Trainer PJ - Search Results

1

Gender and age influence the relationship between serum GH and IGF-I in patients with acromegaly.

Parkinson C, Renehan AG, Ryder WD, O'Dwyer ST, Shalet SM, Trainer PJ. Parkinson C, et al. Among authors: trainer pj. Clin Endocrinol (Oxf). 2002 Jul;57(1):59-64. doi: 10.1046/j.1365-2265.2002.01560.x. Clin Endocrinol (Oxf). 2002. PMID: 12100070

2

Seeking the optimal target range for insulin-like growth factor I during the treatment of adult growth hormone disorders.

Mukherjee A, Monson JP, Jönsson PJ, Trainer PJ, Shalet SM; KIMS International Board. Mukherjee A, et al. Among authors: trainer pj. J Clin Endocrinol Metab. 2003 Dec;88(12):5865-70. doi: 10.1210/jc.2002-021741. J Clin Endocrinol Metab. 2003. PMID: 14671182

3

Quality of life (QOL) in patients with acromegaly is severely impaired: use of a novel measure of QOL: acromegaly quality of life questionnaire.

Rowles SV, Prieto L, Badia X, Shalet SM, Webb SM, Trainer PJ. Rowles SV, et al. Among authors: trainer pj. J Clin Endocrinol Metab. 2005 Jun;90(6):3337-41. doi: 10.1210/jc.2004-1565. Epub 2005 Mar 8. J Clin Endocrinol Metab. 2005. PMID: 15755865

4

Gender, body weight, disease activity, and previous radiotherapy influence the response to pegvisomant.

Parkinson C, Burman P, Messig M, Trainer PJ. Parkinson C, et al. Among authors: trainer pj. J Clin Endocrinol Metab. 2007 Jan;92(1):190-5. doi: 10.1210/jc.2006-1412. Epub 2006 Oct 31. J Clin Endocrinol Metab. 2007. PMID: 17077131 Clinical Trial.

5

Treatment of acromegaly improves quality of life, measured by AcroQol.

Paisley AN, Rowles SV, Roberts ME, Webb SM, Badia X, Prieto L, Shalet SM, Trainer PJ. Paisley AN, et al. Among authors: trainer pj. Clin Endocrinol (Oxf). 2007 Sep;67(3):358-62. doi: 10.1111/j.1365-2265.2007.02891.x. Epub 2007 Jun 6. Clin Endocrinol (Oxf). 2007. PMID: 17555502

6

High levels of 150-kDa insulin-like growth factor binding protein three ternary complex in patients with acromegaly and the effect of pegvisomant-induced serum IGF-I normalization.

Parkinson C, Flyvbjerg A, Trainer PJ. Parkinson C, et al. Among authors: trainer pj. Growth Horm IGF Res. 2004 Feb;14(1):59-65. doi: 10.1016/j.ghir.2003.08.004. Growth Horm IGF Res. 2004. PMID: 14700556 Clinical Trial.

7

Growth hormone receptor antagonists therapy for acromegaly.

Parkinson C, Trainer PJ. Parkinson C, et al. Among authors: trainer pj. Baillieres Best Pract Res Clin Endocrinol Metab. 1999 Oct;13(3):419-30. doi: 10.1053/beem.1999.0032. Baillieres Best Pract Res Clin Endocrinol Metab. 1999. PMID: 10909433 Review.

8

Pegvisomant: a growth hormone receptor antagonist for the treatment of acromegaly.

Parkinson C, Trainer PJ. Parkinson C, et al. Among authors: trainer pj. Growth Horm IGF Res. 2000 Apr;10 Suppl B:S119-23. doi: 10.1016/s1096-6374(00)80023-4. Growth Horm IGF Res. 2000. PMID: 10984267 Review.

9

Successful treatment of resistant acromegaly with a growth hormone receptor antagonist.

Drake WM, Parkinson C, Akker SA, Monson JP, Besser GM, Trainer PJ. Drake WM, et al. Among authors: trainer pj. Eur J Endocrinol. 2001 Oct;145(4):451-6. doi: 10.1530/eje.0.1450451. Eur J Endocrinol. 2001. PMID: 11581004

10

Clinical use of a growth hormone receptor antagonist in the treatment of acromegaly.

Drake WM, Parkinson C, Besser GM, Trainer PJ. Drake WM, et al. Among authors: trainer pj. Trends Endocrinol Metab. 2001 Nov;12(9):408-13. doi: 10.1016/s1043-2760(01)00461-1. Trends Endocrinol Metab. 2001. PMID: 11595543 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

205 results

Search Page